Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, a consumer health company focused on everyday health brands (e.g., Advil, Centrum, Panadol), covers the month of May 2026. The report, dated May 11, 2026, details aggregated transactions in the company's own shares under a share buyback programme announced on March 12, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Total Shares Purchased: 10,205,329 ordinary shares for cancellation.
- Share Price Range: Purchases occurred between a low of 329.40 pence and a high of 340.50 pence per share.
- Registered Share Capital: 8,880,262,266 ordinary shares of £0.01 each.
- Treasury Shares: 12,184,020 shares held as treasury shares.
- Voting Shares: 8,868,078,246 ordinary shares with voting rights.
Material Changes
The primary material change is the reduction in the number of outstanding shares due to the cancellation of 10,205,329 shares purchased between May 5 and May 8, 2026, across the London Stock Exchange, CBOE (UK)/BXE, CBOE (UK)/CXE, and Aquis venues.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial performance, or discussion of risks and contingencies. It is a regulatory disclosure of share transactions required under the Market Abuse Regulation (EU) No 596/2014 as applied in the UK.
Investor Verification Checklist
- Verify the total cost of the buyback by multiplying the volume-weighted average prices by the share volumes for each trading venue.
- Confirm the updated share count for voting rights calculations (8,868,078,246) against the company's latest capital structure.
- Review the full trade breakdown available via the provided RNS link for granular transaction data.
- Check subsequent filings for the remaining authorization under the March 12, 2026 buyback programme.